SG Americas Securities
DMAC icon

SG Americas Securities’s DiaMedica Therapeutics DMAC Stock Holding History

SG Americas Securities’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,878
Closed -$41K – 3094
2025
Q1 		$41K Buy
+10,878
New +$62.2K ﹤0.01% 3281

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities's DMAC Position: Q2 2025 in Review

SG Americas Securities sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 10,878 shares — an estimated $41K sold.

SG Americas Securities first reported a position in DMAC in Q1 2025 and held it in 1 quarter. The position peaked at $41K in Q1 2025. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

  • SG Americas Securities reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 10,878 DiaMedica Therapeutics shares in Q2 2025, an estimated $41K.
  • SG Americas Securities first reported a position in DiaMedica Therapeutics in Q1 2025 and held it in 1 quarter.
  • SG Americas Securities's DiaMedica Therapeutics position peaked at $41K in Q1 2025.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.